24 Oct Topical corticosteroids – DHCPL – Risk of withdrawal reactions
Posted at 12:37h
in
2022 Oct...
Archive
19 Aug Adverse Drug Reactions and Quality Problem Reporting Form
Posted at 13:47h
in
Adverse Drug Reactions and Quality Problem Reporting Form - for both public and private sector and includes herbal products....
18 Aug Anagrelide hydrochloride: Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation
Posted at 12:07h
in
Takeda (Pty) Ltd, as directed by the South African Health Products Regulatory Authority (SAHPRA), wish to inform you about the risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation of anagrelide hydrochloride....
17 Aug Cefepime hydrochloride – Risk of serious adverse reactions
Posted at 13:09h
in
Risk of serious adverse reactions, including encephalopathy, associated with MAXIPIME (cefepime hydrochloride) particularly in patients with renal impairment who received doses that exceeded the dosage recommendations. ...
17 Aug Valproate containing medicines – High risk of congenital abnormalities and development disorders
Posted at 13:07h
in
Aspen Pharmacare, Brimpharm SA (Pty) Ltd, Adcock Ingram Limited, Sandoz SA (Pty) Ltd and Takeda (Pty) Ltd in collaboration with the South African Health Products Regulatory Authority (SAHPRA) would like to inform you of the risks related to the use of valproate containing medicines (sodium...
17 Aug Clozapine – Induced gastrointestinal hypomotility
Posted at 13:06h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA) Novartis, Litha Pharma and Aspen Pharmacare, would like to remind you of the following labelled safety information regarding the safe use of clozapine as contained in: ...
17 Aug Hydrochlorothiazide – Risk of non-menoloma skin cancer
Posted at 13:04h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a new risk of non-melanoma skin cancer (NMSC) (basal cell carcinoma, squamous cell carcinoma) in patients treated with hydrochlorothiazide....
17 Aug Lamotrigine – Risk of Hemophagocytic Lymphohistiocytosis
Posted at 13:03h
in
In agreement with the South African Health Products Regulatory Authority (SAHPRA), Aurobindo Pharma (Pty) Ltd would like to inform you of the following important information regarding the risk of Hemophagocytic Lymphohistiocytosis (HLH) associated with the use of lamotrigine containing medicines....
17 Aug Hyoscine Butylbromide – Risk of adverse effects in patients with underlying cardiac disease
Posted at 13:02h
in
lngelheim Pharmaceuticals (Pty) Ltd and Sanofi-Aventis South Africa (Pty) Ltd in collaboration with SAHPRA wish to inform you of the following safety information update regarding the use of hyoscine butylbromide injection as contained in BUSCOPAN 20 mg/1 ml ampoules and BUSCOPAN COMPOSITUM 20 mg/2,5 g...
17 Aug Amphotericin B – Risk of Medication Error
Posted at 13:01h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA) Bristol-Myers Squibb and Key Oncologies (Ply) Ltd would like to draw your attention to the risk of errors in prescribing, dispensing, preparing and administering different parenteral formulations of amphotericin B. ...